title: GLP-1-based therapies: the dilemma of uncertainty.
authors: Joachim
authors: J
authors: Spranger
authors: Ursula
authors: U
authors: Gundert-Remy
authors: Thomas
authors: T
authors: Stammschulte
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D000077270:Exenatide; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D010190:Pancreatic Neoplasms / Q000139:chemically induced*; D010195:Pancreatitis / Q000139:chemically induced*; D010455:Peptides / Q000009:adverse effects; D011719:Pyrazines / Q000009:adverse effects; D018027:Receptors, Glucagon / Q000819:agonists*; D018570:Risk Assessment; D012307:Risk Factors; D000068900:Sitagliptin Phosphate; D013964:Thyroid Neoplasms / Q000139:chemically induced*; D014230:Triazoles / Q000009:adverse effects; D035501:Uncertainty; D014688:Venoms / Q000009:adverse effects
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D010455:Peptides; D011719:Pyrazines; D018027:Receptors, Glucagon; D014230:Triazoles; D014688:Venoms; D000077270:Exenatide; D000068900:Sitagliptin Phosphate